Lumito

0,02 SEK

0,00 %

Mindre end 1K følgere

LUMITO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

0,00 %

-61,36 %

-79,91 %

-89,98 %

-92,05 %

-90,43 %

-96,90 %

-98,84 %

-96,51 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Markedsværdi

29,25 mio. SEK

Aktieomsætning

78,97 t SEK

Omsætning

100 t

EBIT %

-38.300 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning t

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

20.2

2026

Årsrapport '25

7.5

2026

Generalforsamling '26

7.5

2026

Delårsrapport Q1'26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse5.12.2025, 13.15

Nomination Committee for Lumito appointed ahead of the 2026 Annual General Meeting

Selskabsmeddelelse2.12.2025, 07.30

Lumito Appoints Chief Business Officer to accelerate commercial growth

Selskabsmeddelelse27.11.2025, 07.30

Lumito AB publishes interim report for the third quarter of 2025

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse25.11.2025, 09.00

Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report

Selskabsmeddelelse21.11.2025, 08.45

Lumito granted SEK 250,000 business development grant from Region Skåne

Selskabsmeddelelse19.11.2025, 15.45

Conversion of paid subscribed units (BTUs) and first day of trading in warrants of series TO7

Pressemeddelelse19.11.2025, 06.47

BioStock: Video from Lumito's presentation at BioStock Life Science Summit 2025

Selskabsmeddelelse11.11.2025, 21.30

Lumito's Board of Directors resolves on a directed share issue of units to guarantors in connection with the completed rights issue

Selskabsmeddelelse3.11.2025, 18.10

Lumito announces outcome in rights issue

Selskabsmeddelelse29.10.2025, 08.30

Truly Labs AB include Lumito’s tissue analysis technology into its customer offering

Selskabsmeddelelse27.10.2025, 07.30

Last day of trading with unit rights in Lumito’s rights issue

Selskabsmeddelelse23.10.2025, 06.30

Lumito AB and Katana Labs GmbH sign Letter of Intent and enter into a strategic partnership to enhance biomarker detection and quantification

Selskabsmeddelelse22.10.2025, 16.00

Investor presentation from Financial Stockholm is now available

Selskabsmeddelelse17.10.2025, 11.15

Lumito presents at Financial Stockholm on the 21st of October

Selskabsmeddelelse16.10.2025, 06.30

The subscription period in Lumito’s rights issue of units starts today

Selskabsmeddelelse15.10.2025, 10.00

Concept Life Sciences adds Lumito's tissue analysis solution to its customer offering following positive results from the SCIZYS platform evaluation

Selskabsmeddelelse13.10.2025, 09.50

Lumito AB publishes prospectus in connection with rights issue of units of approximately SEK 60 million

Selskabsmeddelelse7.10.2025, 06.00

Lumito AB announces terms of rights issue of units of approximately SEK 60 million

Selskabsmeddelelse3.10.2025, 13.10

Lumito AB publishes white paper on the use of SCIZYS for high-sensitivity analysis of the breast cancer biomarker HER2 in tissue

Selskabsmeddelelse2.10.2025, 09.45

Lumito AB at Biomarkers & Precision Medicine UK, NLSDays and Pharma Outsourcing

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.